Cardio Diagnostics (CDIO) Regains Nasdaq Compliance

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Requirement”) for continued listing on The Nasdaq Capital Market. This was disclosed in the Company’s Current Report on Form 8-K filed on May 28, 2025.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s common stock traded above $1.00 per share from May 13, 2025, the date immediately following the Company’s 1:30 reverse stock split having gone effective, through May 27, 2025. Accordingly, Nasdaq determined that the Company has regained compliance with Nasdaq’s Minimum Bid Requirement, and that Nasdaq considered the matter closed.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• VivoPower shifts focus to AI data centers, revises unit spinoff plans
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight